Formulation and Characterization of Nanoemulsion of Olanzapine for Intranasal Delivery

References

1. 1.↵
   1. Bodor N.,
   2. Buchwald P.

   Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discovery Today 2002, 7 ( 14), 766– 774.

   OpenUrlPubMedGoogle Scholar
2. 2.↵
   1. Soni V.,
   2. Chaurasia M. K.,
   3. Gupta Y.,
   4. Jain A.,
   5. Kohli D. V.,
   6. Jain S. K.

   Novel approaches for drug delivery to the brain. Ind. J. Pharm. Sci. 2004, 66 ( 6), 711– 720.

   OpenUrlGoogle Scholar
3. 3.↵
   1. Astic L.,
   2. Saucier D.,
   3. Coulon P.

   The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice. Brain Res. 1993, 619 ( 1–2), 146– 156.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
4. 4.↵
   1. Braso A.,
   2. Princep M.,
   3. Schmid M.,
   4. Tabernero A.,
   5. Perez C.,
   6. Guglietta A.

   Developmental pharmacology: Behavior assay in antipsychotics. Methods Findings Exp. Clin. Pharmacol. 2003, 25, 1– 2.

   OpenUrlPubMedGoogle Scholar
5. 5.↵
   Food and Drug Administration (April 2007). Electronic Orange Book. Retrieved on May 24, 2007.

   Google Scholar
6. 6.↵
   1. Keck P. E.,
   2. Elray L. M.

   Clinical pharmacodynamics and pharmacokinetics of antimanic and mood stabilizing medications. J. Clin. Psychiatry 2002, 63 ( 4), 3– 11.

   OpenUrlGoogle Scholar
7. 7.↵
   1. Chien Y. W.,
   2. Su K. S. E.

   1. Chien Y. W.

   Nasal Drug Delivery and Delivery Systems. In Nasal Systemic Drug Delivery; Chien Y. W., Su K. S. E. Eds. Marcel Dekker, Inc.: New York, 1989, p 239.

   Google Scholar
8. 8.↵
   1. Green B.

   Focus on olanzapine. Curr. Med. Res. Opin. 1999, 15 ( 2), 79– 85.

   OpenUrlPubMedGoogle Scholar
9. 9.↵
   1. Wirshing D. A.,
   2. Wirshing W. C.,
   3. Kysar L.,
   4. Berisford M. A.

   Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psych. 1999, 60 ( 6), 358– 363.

   OpenUrlPubMedWeb of ScienceGoogle Scholar
10. 10.↵
    1. Sakane T.,
    2. Yamashita S.,
    3. Yata N.,
    4. Sezaki H.

    Transnasal delivery of 5-fluorouracil to the brain in the rat. J. Drug Target. 1999, 7 ( 3), 233– 240.

    OpenUrlPubMedWeb of ScienceGoogle Scholar
11. 11.↵
    1. Candace L. G.,
    2. Pollock G. M.

    Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci. 2005, 94 ( 6), 187– 195.

    OpenUrlGoogle Scholar
12. 12.↵
    1. Illum L.

    Nasal drug delivery: new developments and strategies. D.D.T. 2002, 7 ( 23), 1184– 1189.

    OpenUrlPubMedGoogle Scholar
13. 13.↵
    1. Vyas T. K.,
    2. Babbar A. K.,
    3. Sharma R. K.,
    4. Singh S.,
    5. Misra A.

    Preliminary brain targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech 2006, 7 ( 1), E1– E9.

    OpenUrlPubMedGoogle Scholar
14. 14.↵
    1. Vyas T. K.,
    2. Babbar A. K.,
    3. Sharma R. K.,
    4. Singh S,
    5. Misra A.

    Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci. 2006, 95 ( 3), 570– 580.

    OpenUrlPubMedGoogle Scholar
15. 15.↵
    1. Chow H. S.,
    2. Chen Z.,
    3. Matsuura G. T.

    Direct transport of cocaine from the nasal cavity to brain following intranasal cocaine administration in rats. J. Pharm. Sci. 1999, 88 ( 8), 754– 758.

    OpenUrlCrossRefPubMedGoogle Scholar
16. 16.↵
    1. Kumar M.,
    2. Mishra A. N.,
    3. Mishra A. K.,
    4. Babbar A. K.,
    5. Mishra P.,
    6. Pathak K.

    Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008, 358 ( 1–2), 285– 291.

    OpenUrlPubMedGoogle Scholar
17. 17.↵
    1. Behl C. R.,
    2. Pimplaskar H. K.,
    3. Sileno A. P.,
    4. De Meireles J.,
    5. Romeo V. D.

    Effects of physicochemical properties and other factors on systemic nasal delivery. Adv. Drug Del. Rev. 1998, 29 ( 1–2), 89– 116.

    OpenUrlPubMedGoogle Scholar
18. 18.↵
    1. Pietrowky R.,
    2. Thieman A.,
    3. Kern W.,
    4. Fehm H. L.,
    5. Bern J.

    A nose-brain pathway for psychotropic peptides, evidence from a brain evolved potential study with cholecystokinin. Psychoneuroendocrino 1996, 21, 559– 572.

    OpenUrlGoogle Scholar
19. 19.↵
    1. Qizhi Z.,
    2. Jiang X.,
    3. Xiang W.,
    4. Lu W.,
    5. Su L.,
    6. Shi Z.

    Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int. J. Pharm. 2004, 275 ( 1–2), 85– 96.

    OpenUrlPubMedGoogle Scholar
20. 20.↵
    1. Vyas T. K.,
    2. Shahiwala A.,
    3. Marathe S.,
    4. Misra A.

    Intranasal drug delivery for brain targeting. Curr. Drug Del. 2005, 2 ( 2), 165– 175.

    OpenUrlGoogle Scholar
21. 21.↵
    1. Lawrence M. J.,
    2. Rees G. D.

    Microemulsion based media as a novel drug delivery system. Adv. Drug Del. Rev. 2000, 45 ( 1), 89– 121.

    OpenUrlPubMedGoogle Scholar
22. 22.↵
    1. Ugwoke M. I.,
    2. Verbeke N.,
    3. Kinget R.

    The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53 ( 1), 3– 21.

    OpenUrlPubMedGoogle Scholar
23. 23.↵
    1. Illum L.

    Nasal drug delivery: Problems, possibilities and solutions. J. Controlled Release 2003, 87 ( 1–3), 187– 198.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
24. 24.↵
    1. Boonme P.,
    2. Graf A.,
    3. Rades T.,
    4. Junyapraser V. B.

    Characterization of microemulsion structures in the pseudo-ternary phase diagram of isopropyl palmitate/water/Brij 97:1-butanol. AAPS PharmSciTech 2006, 7 ( 2), E99– E104.

    OpenUrlGoogle Scholar
25. 25.↵
    1. Ghosh P. K.,
    2. Majithiya R. J.,
    3. Umrethia M. L.,
    4. Murthy R. S. R.

    Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 2006, 7 ( 3), Article 77.

    Google Scholar
26. 26.↵
    1. Rolan I.,
    2. Piel G.,
    3. Delattre L.,
    4. Evrard B.

    Systemic characterization of oil-in-water emulsions for formulation design. Int. J. Pharm. 2003, 263, 85– 94.

    OpenUrlPubMedGoogle Scholar
27. 27.↵
    1. Avis K. A.,
    2. Lieberman H. A.,
    3. Lachman L.

    Pharmaceutical Dosage Forms: Parenteral Medications; 2nd ed.; Marcel Dekker, Inc.: New York, 1986; Vol. 2, p 562.

    OpenUrlGoogle Scholar
28. 28.↵
    1. Sinswat P.,
    2. Tengamuay P.

    Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats; comparison with hydroxypropyl and dimethyl-beta-cyclodextrins. Int. J. Pharm. 2003, 257 ( 1–2), 15– 22.

    OpenUrlPubMedGoogle Scholar
29. 29.↵
    1. Gavini E.,
    2. Rassu G.,
    3. Sanna V.,
    4. Cossu M.,
    5. Giunchedi P.

    Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J. Pharm. Pharmacol. 2005, 57 ( 3), 287– 94.

    OpenUrlPubMedGoogle Scholar
30. 30.↵
    1. Gavini E.,
    2. Rassu G.,
    3. Muzzarelli C.,
    4. Cossu M.,
    5. Giunchedi P.

    Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur. J. Pharm. Biopharm. 2008, 68 ( 2), 245– 252.

    OpenUrlPubMedGoogle Scholar
31. 31.↵
    1. Craig D. Q. M.,
    2. Barker S. A.,
    3. Banning D.,
    4. Booth S. W.

    An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharm. 1995, 114 ( 1), 103– 110.

    OpenUrlGoogle Scholar
32. 32.↵
    1. Kawakami K.,
    2. Yoshikawa T.,
    3. Moroto Y.

    Microemulsion formulation for enhanced absorption of poorly soluble drugs, I: prescription design. J. Controlled Release 2002, 81 ( 1–2), 65– 74.

    OpenUrlCrossRefPubMedGoogle Scholar
33. 33.↵
    1. Gavini E.,
    2. Hegge A. B.,
    3. Rassu G.,
    4. Sanna V.,
    5. Testa C.,
    6. Pirisino G.,
    7. Karlsen J.,
    8. Giunchedi P.

    Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int. J. Pharm. 2006, 307 ( 1), 9– 15.

    OpenUrlPubMedGoogle Scholar